Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Nexcella

nexcella.com ↗

Clinical Phase 3

Keywords: immunoglobulin light chain amyloidosis Light Chain (AL) Amyloidosis NXC-201 NXC-201 CAR-T

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

2027-01 Trial start 3: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amylo source ↗
Jun 5, 2024 Trial start Phase 1/Phase 2: Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1/Phase 2 · Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis · NCT06097832
2028-12 (ESTIMATED) · 3 · A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloido · NCT07709715

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07709715	A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis	3	Not yet recruiting	2027-01	2028-12 (estimated)
NCT06097832	Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis	Phase 1/Phase 2	Active, not recruiting	Jun 5, 2024	2026-12 (estimated)